221 related articles for article (PubMed ID: 31831153)
1. [Reporting data of patients receiving CAR T cell therapy into the EBMT registry: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Vasseur A; Karam M; Chaillou D; Colonnese E; Dantin C; Latiere C; Meziane Y; Pereira M; Yakoub-Agha I; Chabannon C; Raus N
Bull Cancer; 2020 Dec; 107(12S):S178-S184. PubMed ID: 31831153
[TBL] [Abstract][Full Text] [Related]
2. [A standardized medical report template for CAR T-Cell therapy patients: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Broussais F; Vasseur A; Karam M; Chaillou D; Pereira M; Yakoub-Agha I; Raus N
Bull Cancer; 2021 Dec; 108(12S):S82-S86. PubMed ID: 33933288
[TBL] [Abstract][Full Text] [Related]
3. [The care process of patient receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Beauvais D; Andrianne C; Aubrun C; Berquier M; Bole S; Caulier A; Courbon C; Delorme J; Fournier I; François G; Jaivenois MF; Le Bars L; Mussot I; Vercasson M; Wallart Brejaud A; Yakoub-Agha I; Lacroix D
Bull Cancer; 2020 Dec; 107(12S):S170-S177. PubMed ID: 32891406
[TBL] [Abstract][Full Text] [Related]
4. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
5. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
[TBL] [Abstract][Full Text] [Related]
6. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
[TBL] [Abstract][Full Text] [Related]
7. [CAR-T CELLS: How does the EBMT registry monitor European activities, identify hurdles and prepare for changes in regulations].
Chabannon C; Lemaitre J; Peffault de Latour R; Neven B; Bay JO; Robin M; Kuball J; Terwel S; Mohty M; Yakoub-Agha I
Bull Cancer; 2021 Oct; 108(10S):S155-S161. PubMed ID: 34920798
[TBL] [Abstract][Full Text] [Related]
8. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Yakoub-Agha I; Chabannon C; Bader P; Basak GW; Bonig H; Ciceri F; Corbacioglu S; Duarte RF; Einsele H; Hudecek M; Kersten MJ; Köhl U; Kuball J; Mielke S; Mohty M; Murray J; Nagler A; Robinson S; Saccardi R; Sanchez-Guijo F; Snowden JA; Srour M; Styczynski J; Urbano-Ispizua A; Hayden PJ; Kröger N
Haematologica; 2020; 105(2):297-316. PubMed ID: 31753925
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
Dushenkov A; Jungsuwadee P
J Oncol Pharm Pract; 2019 Jul; 25(5):1217-1225. PubMed ID: 30890066
[TBL] [Abstract][Full Text] [Related]
10. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
[TBL] [Abstract][Full Text] [Related]
11. Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life.
McGrath E; Chabannon C; Terwel S; Bonini C; Kuball J
Curr Opin Oncol; 2020 Sep; 32(5):427-433. PubMed ID: 32665456
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell product performance in haematological malignancies before and after marketing authorisation.
Elsallab M; Levine BL; Wayne AS; Abou-El-Enein M
Lancet Oncol; 2020 Feb; 21(2):e104-e116. PubMed ID: 32007196
[TBL] [Abstract][Full Text] [Related]
13. Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Yakoub-Agha I
Curr Res Transl Med; 2018 May; 66(2):57-58. PubMed ID: 29685843
[TBL] [Abstract][Full Text] [Related]
14. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Nair R; Neelapu SS
Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
[TBL] [Abstract][Full Text] [Related]
15. [How to capture cytogenetic and molecular abnormalities into ProMISe database for hematological malignancies: Guidelines from the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Raus N; Karam M; Chebel R; Dantin C; Pereira M; Wallart A; Yakoub-Agha I; Srour M
Bull Cancer; 2020 Jan; 107(1S):S52-S61. PubMed ID: 31615645
[TBL] [Abstract][Full Text] [Related]
16. What CAR Will Win the CD19 Race?
Quintás-Cardama A
Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
[TBL] [Abstract][Full Text] [Related]
17. [Follow-up logbook of patients receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Berquier M; Cherel L; Clerc Renaud D; Hospital Gustems C; Wallart Brejaud A; Yakoub-Agha I; Beauvais D
Bull Cancer; 2021 Dec; 108(12S):S39-S44. PubMed ID: 33992416
[TBL] [Abstract][Full Text] [Related]
18. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.
Mahmoudjafari Z; Hawks KG; Hsieh AA; Plesca D; Gatwood KS; Culos KA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):26-33. PubMed ID: 30266675
[TBL] [Abstract][Full Text] [Related]
19. [Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Ferrand C; Chalandon Y; Ballot C; Castilla Llorente C; Deschamps M; Gauthier J; Labalette M; Larghero J; Maheux C; Moreau AS; Varlet P; Pétillon MO; Pinturaud M; Rubio MT; Chabannon C
Bull Cancer; 2017 Dec; 104(12S):S43-S58. PubMed ID: 29174320
[TBL] [Abstract][Full Text] [Related]
20. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].
Broussais F; Bay JO; Boissel N; Baruchel A; Arnulf B; Morschhauser F; Robin M; Guepin GR; Moreau P; Gandemer V; Manier S; Leguay T; Nguyen Quoc S; Schwartzmann A; Houot R; Le Gouill S
Bull Cancer; 2021 Oct; 108(10S):S143-S154. PubMed ID: 34920797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]